enGene Highlights Bladder Cancer Therapy Data and 2027 Path

enGene used a company webinar to present preclinical findings on its investigational non-viral gene therapy, detalimogene voraplasmid, paired with a polidocanol surfactant bladder rinse. The discussion also highlighted the treatment burden facing patients with high-risk non-muscle invasive bladder cancer.




